SEC Form 424B3 filed by Jupiter Neurosciences Inc.
$JUNS
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
New Advisors Bring Nationwide Pharmacy and Wellness Distribution Expertise to Nugevia™ Consumer Longevity Line Compounding Pharmacy and Wellness Channels Represent Over $1.5 Billion Addressable Market for Practitioner-Grade Nutraceuticals in the U.S. JUPITER, FL, April 07, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the appointment of Kristopher Fishman and Sanjiv Lal to the Nugevia™ Advisory Board. The two bring direct distribution relationships across compounding pharmacies and wellness channels, an addressable market th
MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 91st Emerging Growth Conference on April 1 & 2, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 – Presenting TodayWednesday, April 1, 2026 9:00Virtual Lobby opens.Register for the Conference. If you a
JUPITER, FL, March 31, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to announce that it has been invited to present its clinical and commercial progress at the Emerging Growth Conference 91 on April 2, 2026, at 10:15 AM ET. Jupiter invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference at: https://goto.webcasts.com/starthere.jsp?ei=1748971&tp_key=add80b0ab6&sti=juns If attendees are not able to join the event live on the
10-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
NT 10-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
New Advisors Bring Nationwide Pharmacy and Wellness Distribution Expertise to Nugevia™ Consumer Longevity Line Compounding Pharmacy and Wellness Channels Represent Over $1.5 Billion Addressable Market for Practitioner-Grade Nutraceuticals in the U.S. JUPITER, FL, April 07, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced the appointment of Kristopher Fishman and Sanjiv Lal to the Nugevia™ Advisory Board. The two bring direct distribution relationships across compounding pharmacies and wellness channels, an addressable market th